FOR IMMEDIATE RELEASE – August 15, 1997

Integra LifeSciences Organizes Two New Advisory Boards

PLAINSBORO, N.J., Aug. 15 /PRNewswire/ -- Integra LifeSciences Corporation (Nasdaq: IART) today announced the formation of two new advisory boards: a Physicians Advisory Panel and a Clinical Advisory Board.

In making the announcement, Vice Chairman and Chief Operating Officer George W. McKinney, Ph.D. said, "The purpose of these two groups will be to investigate and identify the needs of linicians treating patients with Integra(TM) artificial Skin. Participants will coordinate additional areas for surgical procedures to optimize the effect of Integra(TM) on patients in plastic and reconstructive surgery treatments."

The Company plans to maintain its special Burn Advisory group of prominent burn surgeons who have been instrumental in the Company's clinical trials, and the subsequent commercial launch of Integra(TM) Skin. "These additional advisory boards will focus on developing care procedures for patients who have received Integra Artificial Skin, as well as new applications of the product," said Dr. McKinney.

Integra Medical Director Carlos Blanco, M.D. will head up the Physicians Advisory Panel, which will meet twice a year beginning in September. Dr. Blanco is also a member of the Board of Directors of the Wound Healing Society and a leader in the burn and wound care community. The panel will consist of eight surgeons from across the U.S. and Canada who specialize in plastic and reconstructive surgery, as well as burn care. More surgeons may be added as intensity of usage increases.

"These surgeons are some of the most prominent specialists in this area of medicine. We look forward to a significant increase in the number and scope of publishable clinician studies showing the effectiveness of Integra Artificial Skin," said Dr. Blanco.

The Clinical Advisory Board, made up of nine nurses and physical therapists from the U.S. and Canada, will be under the supervision of Integra Director of Marketing Debbie Leonetti. The Clinical Advisory Board also will hold its first meeting in September.

"We are establishing this advisory board to learn from the experts and to develop a strong working relationship with opinion leaders. The goals of the board's first meeting are to identify the needs of clinicians caring for patients with Integra Artificial Skin in order to develop a peri-operative and post-operative care manual, and to explore the future of burn and scar revision treatments," said Leonetti.

Integra Artificial Skin received marketing approval from the FDA in March 1996 and is the only such medical device that regenerates a new, permanent dermis. Nearly 500 patients throughout the world have been treated with Integra since the FDA approved the product for marketing.

- more -

Integra LifeSciences Corporation is dedicated to the development and manufacture of proprietary BioSmart(TM) absorbable materials-based therapeutic applications and pharmacological products, which are designed to control the behavior of cells within the patient's body, to regenerate tissue that has been irreversibly lost to disease, accident or surgery, or to prevent or cure diseases or age-associated disorders. Integra Artificial Skin is the first of a series of products that the Company is developing to regenerate a variety of body tissues, including articular cartilage and peripheral nerves, which ordinarily do not regenerate themselves.

Please feel free to visit the company Website (http://www.integra-LS.com). Integra LifeSciences Corporation press releases are also available at no charge through PR Newswire's Company News On-Call fax Service. For a menu of Integra LifeSciences Corporation press releases or to retrieve a specific release, call 800-758-5804, extension 106047 or http://www.prnewswire.com on the Internet.

###

Certain statements made in this press release related to development and clinical effectiveness of enhanced applications of INTEGRA Artificial Skin in surgical procedures for plastic and reconstructive surgery treatment, as well as development of burn and scar revision treatments mentioned in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may differ materially from those set forth in these statements. In addition, the economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission could affect such results.